

**ARIANNE PHOSPHATE INC.
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)
THREE-MONTH PERIODS ENDED MARCH 31, 2018 AND MARCH 31, 2017
(in Canadian dollars)**



Condensed consolidated interim financial statements for the three-month period ended March 31, 2018 haven't been reviewed by the auditors.

ARIANNE PHOSPHATE INC.

CONTENTS

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION 3

CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS 4

CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY 5

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS..... 6

ARIANNE PHOSPHATE INC.
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(In Canadian dollars)

	As at March 31, 2018	As at December 31, 2017
ASSETS		
Current assets		
Cash and cash equivalents (note 3)	1,171,609	1,374,881
Receivables and other current assets	74,953	502,748
Sales taxes receivable	95,513	88,953
Tax credit related to resources and mining tax credit receivable	248,883	248,883
	<u>1,590,958</u>	<u>2,215,465</u>
Non-current assets		
Tax credit related to resources and mining tax credit receivable	183,392	151,737
Investment property – Outfitters (note 4)	302,843	308,079
Property, plant and equipment (note 5)	1,625,941	1,630,516
Mining properties (note 6)	1,277,734	1,247,163
Exploration and evaluation assets (note 7)	51,335,248	49,773,697
	<u>54,725,158</u>	<u>53,111,192</u>
	<u>56,316,116</u>	<u>55,326,657</u>
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	1,296,624	1,924,840
Credit line (note 8)	20,494,243	-
	<u>21,790,867</u>	<u>1,924,840</u>
Non-current liabilities		
Credit line (note 8)	-	19,642,554
Loan (note 9)	3,774,786	3,728,306
Deferred income taxes	2,961,513	2,935,567
	<u>28,527,166</u>	<u>28,231,267</u>
Equity		
Capital stock (note 10)	60,194,364	58,828,558
Warrants (note 11)	1,589,038	1,547,839
Contributed surplus	13,366,729	13,315,903
Deficit	(47,361,181)	(46,596,910)
	<u>27,788,950</u>	<u>27,095,390</u>
Total liabilities and equity	<u>56,316,116</u>	<u>55,326,657</u>
GOING CONCERN (note 1)		
COMMITMENTS (note 14)		
EVENTS AFTER REPORTING PERIOD (note 17)		

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ON BEHALF OF THE BOARD
(s) Siva J. Pillay, Director

(s) James Cowley, CFO

ARIANNE PHOSPHATE INC.
CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
FOR THREE-MONTH PERIOD ENDED MARCH 31, 2018

(In Canadian dollars)

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
EXPENSES		
Salaries and benefits	230,002	225,949
Share-based compensation	50,826	74,992
Professional and consultant fees	71,529	191,128
Management fees	47,500	16,500
Registration and listing fees	58,359	37,347
Communications	95,034	85,555
Promotion, representation and travel	12,600	26,546
Insurance	8,746	8,387
Rent and office expenses	67,754	39,493
Depreciation of property, plant and equipment	7,946	11,463
Gain disposal property, plant and equipment	-	(7,898)
Bank charges	459	1,312
Operating loss	650,755	710,774
OTHER EXPENSES (INCOME)		
Interest income	(1,861)	(4,589)
Foreign exchange (gain) loss	1,831	5,594
Net loss of investment property – Outfitters (Note 4)	19,809	17,672
	19,779	18,677
LOSS BEFORE INCOME TAXES	670,534	729,451
Deferred income taxes	25,946	70,254
NET LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD	696,480	799,705
BASIC AND DILUTED LOSS PER SHARE	0.01	0.01
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	105,803,943	97,648,080

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ARIANNE PHOSPHATE INC.
CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY
FOR THREE-MONTH PERIOD ENDED MARCH 31, 2018
(in Canadian dollars)

	Capital stock	Capital stock	Warrants	Contributed surplus	Deficit	Total equity
	Common shares	\$	\$	\$	\$	\$
Balance as at January 1, 2018	103,570,610	58,828,558	1,547,839	13,515,903	(46,596,910)	27,095,390
Net loss and comprehensive loss for the period	-	-	-	-	(696,480)	(696,480)
Share-based compensation (note 11)	-	-	-	50,826	-	50,826
Grant of warrants (note 11)	-	-	41,194	-	-	41,194
Private Placement (note 10)	2,233,333	1,365,806	-	-	-	1,365,806
Share issuance expenses	-	-	-	-	(67,786)	(67,786)
Modification of warrants (note 11)	-	-	5	-	(5)	-
Balance as at March 31, 2018	105,803,943	60,194,364	1,589,038	13,366,729	(47,361,181)	27,788,950
Balance as at January 1, 2017	97,648,080	54,783,402	2,540,438	11,693,008	(42,760,452)	26,256,396
Net loss and comprehensive loss for the period	-	-	-	-	(799,705)	(799,705)
Modification of warrants (note 11)	-	-	15,994	-	(15,994)	-
Share-based compensation	-	-	-	74,992	-	74,992
Balance as at March 31, 2017	97,648,080	54,783,402	2,556,432	11,768,000	(43,576,151)	25,531,683

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ARIANNE PHOSPHATE INC.
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
FOR THREE MONTH PERIOD ENDED MARCH 31, 2018
(in Canadian dollars)

	2018	2017
	\$	\$
CASH FLOW FROM (USED IN)		
OPERATING ACTIVITIES		
Net loss for the year	(696,480)	(799,705)
Adjustments for:		
Share-based payments	50,826	74,992
Depreciation – Investment property - Outfitters	5,236	6,319
Depreciation – Property, plant and equipment	7,946	11,463
Income taxes and deferred taxes	25,946	70,254
Net change in non-cash working capital items (note 12)	(472,073)	(547,915)
	<u>(1,078,599)</u>	<u>(1,184,592)</u>
INVESTING ACTIVITIES		
Acquisition of property, plant and equipment	(6,743)	(15,603)
Acquisition of mining properties	(30,571)	-
Acquisition of exploration and evaluation assets	(416,430)	(570,432)
	<u>(453,744)</u>	<u>(586,035)</u>
FINANCING ACTIVITIES		
Transaction cost	(10,146)	-
Proceeds from the issuance of units	1,407,000	-
Share issuance expenses	(67,786)	-
	<u>1,329,068</u>	<u>-</u>
CHANGE IN CASH AND CASH EQUIVALENTS DURING THE PERIOD	(203,275)	(1,770,627)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,374,881	2,229,044
CASH AND CASH EQUIVALENTS, END OF PERIOD	1,171,606	458,417
Supplementary cash flow information (note 12)		
Interest received	1,861	4,589
Interest paid	-	80,789

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

1. STATUTE OF INCORPORATION, NATURE OF ACTIVITIES AND GOING CONCERN

Arianne Phosphate Inc. ("the Company"), was incorporated under Part IA of the Companies Act (Quebec) and was continued under the Quebec Business Corporations Act (Quebec) (QBCA). The Company is engaged in the acquisition and exploration of mining properties in Quebec, Canada. During 2013, the Company completed a feasibility study on its Lac à Paul property. The Company's objective is to focus on developing a phosphate mine by concentrating its resources on this property. The Company's shares are listed on the TSX Venture Exchange (symbol DAN), on the Frankfurt exchange (symbol JE9N) and on the US Stock Exchange Over-the-Counter (OTC) (symbol DRRSF). The registered office of the Company is located at 393 Racine Street, Suite 200, Chicoutimi, Quebec, Canada G7H 1T2.

Although management has taken steps to verify titles of mining properties in which the Company has an interest, in accordance with industry standards for the current stage of exploration of such properties, these procedures do not guarantee the Company's title. Property title may be subject to unregistered prior agreements and non-compliant with regulatory requirements.

These condensed consolidated interim financial statements have been prepared based on accounting principles applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period. For the period ended March 31, 2018, the Company recorded a net loss of 696,480 (2017 – \$799,705) and has an accumulated deficit of \$47,361,181 as at March 31, 2018 (\$46,596,910 as at December 31, 2017). In addition to ongoing working capital requirements, the Company must secure sufficient funding to meet its obligations and pay general and administration costs.

As at March 31, 2018, the Company had a negative working capital of \$20,199,909 (positive working capital of \$290,625 as at December 31, 2017). Management estimates that the working capital will not be sufficient to meet the Company's obligations and budgeted expenditures through March 31, 2019. These circumstances lend significant doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern. The Company will need to secure additional financing in 2018.

Any funding shortfall may be met in the future in a number of ways including, but not limited to, the issuance of new equity, debt financing or securing capital from potential partners. While management has been successful in securing financing in the past, there can be no assurance that it will be able to do so in the future or that these sources of funding or initiatives will be available to the Company or that they will be available on terms which are acceptable to the Company. If management is unable to obtain new funding, the Company may be unable to continue its operations, and amounts realized for assets might be less than amounts reflected in the condensed consolidated interim financial statements.

These condensed consolidated interim financial statements do not reflect the adjustments to the carrying values of assets and liabilities, expenses and financial position classifications that would be necessary if the going concern assumption was not appropriate. These adjustments could be material.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB").

The accounting policies followed in these condensed consolidated interim financial statements are consistent with those applied in the Company's annual financial statements for the year ended December 31, 2017. These condensed consolidated interim financial statements should be read in conjunction with the Company annual financial statements for the year ended December 31, 2017, which have been prepared in accordance with IFRS as issued by the IASB.

The Board of Directors approved these condensed consolidated interim financial statements on May 23, 2018.

New accounting policies adopted in the current quarter

Financial Instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expires.

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

Financial Assets

Financial assets are initially measured at fair value. If the financial asset is not subsequently accounted for at fair value, then the initial measurement includes transaction costs that are directly attributable to the asset's acquisition or origination. On initial recognition, the Company classifies its financial assets in the following measurement categories:

- measured subsequently at amortized cost; and
- measured subsequently at fair value through net loss.

i) Financial assets measured at amortized cost

A financial asset is subsequently measured at amortized cost, using the effective interest method and net of any impairment loss, if:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial Liabilities

Financial liabilities are initially recorded at fair value net of any directly attributable transaction costs. Subsequent to initial recognition these financial instruments are measured at amortized cost using the effective interest method. Accounts payable and accrued liabilities and credit line are classified as financial liabilities at amortized cost.

Impairment

The Company assesses on a forward-looking basis the expected credit loss associated with its debt instruments carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Company applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables.

New Accounting Standards and Interpretations

New standards and interpretations adopted

IFRS 9 – Financial Instruments

On January 1, 2018, the Company adopted *IFRS 9, Financial Instruments* which replaced *IAS 39, Financial Instruments: Recognition and Measurement*, bringing together all three aspects of the accounting for financial instruments: classification and measurement; impairment. The Company applied IFRS 9 retrospectively with restatement of prior periods, but there were no impact on the opening balance sheet as of January 1, 2017 and the comparative information presented.

i) Assets and liabilities

IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward in IFRS 9.

The following table summarizes the classification and measurement changes for the Company's financial assets and liabilities as of January 1, 2017 and 2018:

	Category under IAS 39	Category under IFRS 9
Financial assets :		
Cash and cash equivalents	Loans and receivables	Amortized cost
Financial liabilities :		
Payables and accrued liabilities	Amortized cost	Amortized cost
Loan	Amortized cost	Amortized cost
Crédite Line	Amortized cost	Amortized cost

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

The accounting for these instruments and the line item in which they are included in the consolidated statements of financial position are unaffected by the adoption of IFRS 9, and no measurement adjustments are required to the Company's financial assets and liabilities.

ii) Impairment of financial assets

The adoption of IFRS 9 had no impact on the impairment of the Corporation's financial assets.

Amendments to IFRS 2, *Classification and Measurement of Share-based Payment Transactions* ("IFRS 2")

On June 2016, the IASB issued amendments to IFRS 2 Share-based Payment, clarifying how to account for certain types of share-based payment transactions.

The amendments, which were developed through the IFRS Interpretations Committee, provide requirements on the accounting for:

- the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments;
- share-based payment transactions with a net settlement feature for withholding tax obligations; and
- a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled.

The Company has determined that there is no impact upon the adoption of the amendments to IFRS 2 on January 1, 2018.

3. CASH AND CASH EQUIVALENTS

	As at March 31, 2018	As at December 31, 2017
	\$	\$
Cash and cash equivalents	1,171,609	1,374,881

As at March 31, 2018, cash and cash equivalents comprises cash on hand amounting to \$1,054,914 bearing interest at a fixed rate 0.80% and an amount of \$116,695 not bearing interest. An amount of \$30,000 is restricted in connection with the Company's credit card agreement.

As at December 31, 2017, cash and cash equivalents comprise cash on hand amounting to \$1,162,728 bearing interest at a fixed rate 0.80% and an amount of \$212,152 not bearing interest.

4. INVESTMENT PROPERTY – OUTFITTERS

The following table summarizes the information related to the net loss of investment property – Outfitters:

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
Outfitters income	-	25
Operating expenses:		
Management fees	1,399	1,153
Repair and maintenance	1,583	1,011
Supplies	1,046	1,153
Advertising, promotion and travel	4,090	1,631
Taxes and licenses	2,712	2,728
Insurance	3,494	3,432
Interest and bank charges	249	270
Depreciation of property, plant and equipment	5,236	6,319
	19,809	17,697
Net loss of investment property – Outfitters	19,809	17,672

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

5. PROPERTY, PLANT AND EQUIPMENT

	Leasehold improvements \$	Tools and equipment \$	Computer equipment \$	Land \$	Total \$
Cost					
Balance as at January 1, 2017	294,032	106,240	16,184	812,031	1,228,487
Acquisition	-	20,775	954	614,441	636,170
Balance as at December 31, 2017	294,032	127,015	17,138	1,426,472	1,864,657
Acquisition	-	-	-	6,743	6,743
Balance as at March 31, 2018	294,032	127,015	17,138	1,433,215	1,871,400
Accumulated depreciation					
Balance as at January 1, 2017	108,212	69,639	7,204	-	185,055
Depreciation	35,374	11,278	2,434	-	49,086
Balance as at December 31, 2017	143,586	80,917	9,638	-	234,141
Depreciation	7,398	3,372	548	-	11,318
Balance as at March 31, 2018	150,984	84,289	10,186	-	245,459
Net book value					
Balance as at January 1, 2017	185,820	36,601	8,980	812,031	1,043,432
Balance as at December 31, 2017	150,446	46,098	7,500	1,426,472	1,630,516
Balance as at March 31, 2018	143,048	42,726	6,952	1,433,215	1,625,941

6. MINING PROPERTIES

	Royalties (NSR) %	Balance as at December 31, 2017 \$	Additions \$	Impairments \$	Disposal \$	Balance as at March 31, 2018 \$
Properties in Quebec						
Lac à Paul (100%)	2.25	1,247,163	30,571	-	-	1,277,734

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

7. EXPLORATION AND EVALUATION ASSETS

	Balance as at December 31, 2017	Additions	Tax credits	Impairments	Disposals	Balance as at March 31, 2018
	\$	\$	\$	\$	\$	\$
Quebec						
Lac à Paul	49,773,697	1,593,206	(31,655)	-	-	51,335,248

For the three-month periods ended March 31, 2018 and 2017, the following expenses, related to discovery of mineral resources, have been included in the cost of exploration and evaluation assets:

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
Camp, travel and lodging and general expenses	31,470	33,863
Planning and supervision	109,106	221,559
Professional fees and independent technical reports	457,618	715,521
Borrowing costs	991,640	587,388
Depreciation of property, plant and equipment	3,372	2,764
	<u>1,593,206</u>	<u>1,561,095</u>
Tax credits related to resources and mining tax credit	(31,655)	(96,499)
	<u>1,561,551</u>	<u>1,464,596</u>
Balance – Beginning of period	49,773,697	44,741,815
Balance – End of period	<u>51,335,248</u>	<u>46,206,411</u>

8. CREDIT LINES

In August 2012 and July 2013, the Company entered into agreements to obtain a non-revolving credit line, with Mercury Financing Corp. (the "Lender"), for authorized amounts of respectively \$10 million and \$2.5 million to finance a feasibility study for the Lac à Paul property and to cover the general and administrative expenditures related to this property. Terms and conditions are essentially the same for both agreements.

Interest was capitalized quarterly until the earlier of the following dates: (a) December 31, 2013 for the August 2012 agreement and June 30, 2014 for the June 2013 agreement or (b) the date at which time the Company raises cumulative net cash proceeds of at least \$21 million by way of equity, debt or other instruments. Subsequently, interest was payable quarterly until maturity.

On October 20, 2015, the Company obtained a third non-revolving credit line amounting to \$4,566,887, bearing interest at a fixed rate of 6.25% per annum, to finance exclusively the general and administrative operations and other activities related to the project development for the Lac à Paul project.

In December 2017, the Company has extended its credit line until January 15, 2019. The credit line now bears interest at an annual rate equal to 15%, with all interests capitalized to the principal amount until the credit line matures. In connection with this transaction, the Company will pay to the lender a commitment fee of 3% of the total amount of the credit facility, due on January 15, 2019. At the closing, the parties have also agreed to terminate 3,717,000 non-transferable warrants, which were issued to the lender in October 2015.

In connection with the extension of the credit line, the Company granted 17,181,739 warrants at an exercise price of \$0.68 per warrant. Each warrant entitles the Lender to purchase one common share of the Company and shall be exercisable until January 15, 2019. The warrants are subject to a hold period of four months and one day from the date of the issuance. An amount of \$nil was allocated to the fair value of the warrants.

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

	Three-month period ended March 31, 2018	As at December 31, 2017
	\$	\$
Balance – Beginning of period	19,642,554	17,396,288
Proceeds from credit line	-	291,887
Transaction costs	(10,146)	(57,790)
Capitalized interests	861,835	1,332,510
Amortization of transaction costs	-	679,659
Balance – End of period	<u>20,494,243</u>	<u>19,642,554</u>

On April 21, 2017, the Company closed on a \$1.4 Million credit line with Ocean Partners. The credit line bears interest at 12.5% on any funds drawn, paid monthly commencing on the date of first advance. The maturity date of this credit line was December 27, 2017 but was repayable as tax credits were received. Any amounts received as tax credits reduced the amount available to draw on the credit line.

	Three-month period ended March 31, 2018	As at December 31, 2017
	\$	\$
Balance – Beginning of period	-	-
Proceeds from credit line	-	983,344
Accrued interests	-	21,168
Amount repaid	-	(1,004,512)
Balance – End of period	<u>-</u>	<u>-</u>

9. LOAN

In September 2016, the Company closed on a \$3 million loan agreement with various third-party lenders (the "Loan"). The loan bears interest at 8%, paid semi-annually, and has a maturity of 3 years. The Company had the ability to repay the loan after one year at its option. As part of the loan, the Company issued 2,400,000 non-transferable warrants (refer to note 14), with each warrant entitling the holder to purchase one common share of the Company at a price of \$1.25 per share for a term of 3 years expiring on September 28, 2019. The fair value of those warrants represents \$266,708, calculated with the Black- Scholes model. Additionally, following the expiry of the regulatory hold period, should the closing price of the Company's common shares on the TSX Venture Exchange be equal to or higher than \$2 for 10 consecutive days, the Company shall have the right to force the exercise of the warrants by providing the warrant holders with a 30-day notice period, following which the warrants will automatically expire. The Company also issued 96,000 broker warrants related to this loan at a price of \$0.92 per share for a term of 3 years expiring on September 28, 2019. The fair value of the broker warrants is \$23,026, calculated using the Black- Scholes model.

In October 2016, the Company closed on a \$1.1 million loan agreement with various third-party lenders. The loan bears interest at 8%, paid semi-annually and has a maturity of 3 years. The Company had the ability to repay the loan after one year at its option. As part of the loan, the Company issued 880,000 non-transferable warrants (refer to note 14), with each warrant entitling the holder to purchase one common share of the Company at a price of \$1.25 per share for a term of 3 years expiring on October 27, 2019. The fair value of those warrants represents \$84,961, calculated with the Black- Scholes model. Additionally, following the expiry of the regulatory hold period, should the closing price of Arianne's common shares on the TSX Venture Exchange be equal to or higher than \$2 for 10 consecutive days, the Company shall have the right to force the exercise of the warrants by providing the warrant holders with a 30-day notice period, following which the warrants will automatically expire. The Company also issued 35,200 non-transferable warrants. Each warrant is exercisable at \$0.89 for a period of 3 years expiring on October 27, 2019. The fair value of the broker warrants is \$7,456 and is calculated using the Black- Scholes model. An amount of accrued interest of \$80,789 is included in the accounts payable and accrued liabilities

	Three-month period ended March 31, 2018	As at December 31, 2017
	\$	\$
Balance – Beginning of period	3,728,306	3,551,692
Amortization of transaction costs	46,480	176,614
Balance – End of period	<u>3,774,786</u>	<u>3,728,306</u>

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

10. CAPITAL STOCK

Authorized

Unlimited number of common shares without par value

Unlimited number of preferred shares, without par value, issuable in series: Series A includes 500,000 preferred shares, non-voting, non-cumulative dividend of 8% redeemable by the Company at the amount paid-in.

Changes in the Company's common shares were as follows:

	Three-month period ended March 31, 2018		Three-month period ended March 31, 2017	
	Number	Amount \$	Number	Amount \$
Balance – Beginning of year	103,570,610	58,828,558	97,648,080	54,783,402
Private placement ⁽¹⁾	2,233,333	1,365,806	-	-
Balance – End of period	<u>105,803,943</u>	<u>60,194,364</u>	<u>97,648,080</u>	<u>54,783,402</u>

As at March 31, 2018, 105,803,943 shares are issued and fully paid (2017 – 97,648,080).

(1) Value of capital stock paid in cash (private placement) is presented net of fair value of warrants units amounting to \$41,194 (2017 – nil) – refer to description below.

On March 15, 2018 the Company has closed on a \$1,407,000 financing. Under the terms of the offering, the Government of Quebec subscribed to 2,233,333 Units of the Company (the "Units") at a price of \$0.63 per Unit. The units consist of one common share (the "Common Share") and one half common share purchase warrant (the "Warrant"). Each full Warrant entitles its holder to purchase one common share at a price equal to \$0.85 for a period of thirty-six (36) months following the closing date, expiring on March 14, 2021. If at any time after four (4) months and one (1) day following the closing date, the trading price of the Common Shares on the TSX Venture Exchange is equal to or exceeds \$1.25 for ten (10) consecutive trading days, as evidenced by the price at the close of market, the Company shall be entitled to notify the holders of Warrants of its intention to force the exercise of the Warrants. Upon receipt of such notice, the holders of the Warrants shall have 30 days to exercise the Warrants, failing which the Warrants will automatically expire.

11. STOCK OPTIONS, WARRANTS AND OPTIONS GRANTED TO BROKERS

Stock options

The stock options granted to directors and employees vest on a basis of 33% every year on a three-year period from the date of grant and options to consultants vest on a basis of 25% every three months, starting three months after the grant date.

During the first three months of 2018, 200 000 stock options previously granted to director and consultants, were extended. The fair value of stock options extended amounted to \$331 and was estimated using the Black-Scholes pricing model with the following weighted average assumptions:

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
Weighted average price of share at time of grant	\$0.56	\$0.89
Weighted average risk-free interest rate	1.71%	0.77%
Weighted average expected volatility	30.4%	38.6%
Weighted average expected life	0.33 years	2.0 years
Weighted average expected dividend yield	0%	0%
Weighted average fair value of options granted	0.002	0.21

Company stock options were as follows:

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

	Three-month period ended March 31, 2018		Three-month period ended March 31, 2017	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Balance – Beginning of period	5,842,834	1.03	5,449,500	1.08
Granted	-	-	125,000	0.90
Balance – End of period	<u>5,842,834</u>	1.03	<u>5,574,500</u>	1.04
Exercisable at the end of the period	<u>5,241,167</u>	1.05	<u>4,046,000</u>	1.10

Warrants

Changes in Company warrants were as follows:

	Three-month period ended March 31, 2018		Three-month period ended March 31, 2017	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Balance – Beginning of period	28,640,504	0.90	15,997,500	1.12
Granted	1,116,667	0.85	-	-
Balance – End of period	<u>29,757,171</u>	0.89	<u>15,997,500</u>	1.12

In January 2018, the Company amended the terms and conditions of the 1,217,500 warrants granted on July 29, 2013. Initially, each warrant entitled its holder to acquire one common share at a price of \$1.45 per share until January 27, 2018. These warrants were amended in January 2018 to extend their expiration date to July 2018. All other terms and conditions remained similar. The Company calculated the fair value of the warrants prior and after the amendment. The fair value of the extended warrants was estimated at \$5 considering the fair value of the original warrants existing on the date of the amendment, according to the Black-Scholes model, and it was recorded as an increase in deficit for the three-month period ended March 31, 2018.

Options granted to brokers

Changes in Company options granted to brokers were as follows:

	Three-month period ended March 31, 2018		Three-month period ended March 31, 2017	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Balance – Beginning of period	428,600	0.81	131,200	0.91
Balance – End of period	<u>428,600</u>	0.81	<u>131,200</u>	0.91

12. SUPPLEMENTARY INFORMATIONS RELATED TO CASH FLOWS

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
Net change in non-cash working capital items		
Receivable and other current assets	427,794	60,063
Sales taxes receivable	(6,560)	(64,511)
Accounts payable and accrued liabilities	(893,307)	(543,467)
	<u>(472,073)</u>	<u>(547,915)</u>

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

Items not affecting cash and cash equivalents not otherwise disclosed elsewhere in the condensed consolidated interim financial statements:

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
Addition to exploration and evaluation assets not yet paid	265,091	559,767

13. RELATED PARTY TRANSACTIONS

The table below shows related party transactions and balances payable for each of the Company's related parties:

	Three-month period ended March 31, 2018	Three-month period ended March 31, 2017
	\$	\$
Key management compensation ⁽¹⁾		
Share-based compensation	22,155	21,300
Management fees	47,500	16,500
	<hr/>	<hr/>
	69,655	37,800
Salaries and benefits ⁽²⁾	154,729	87,988
	<hr/>	<hr/>
	224,384	125,788
	<hr/>	<hr/>
Balance included in accounts payable and accrued liabilities	9,732	-

(1) The key management is composed of the Chief executive officer (CEO), Chief Financial Officer (CFO), Chief Operating Officer (COO), Executive Chairman and the vice-president exploration and First Nations Relations.

(2) Salaries and benefits capitalized to exploration and evaluation assets amount to \$57,110 (\$68,166 in 2017).

The Company has entered into employment and management contracts with its key executives whose estimated annual remuneration amounts to \$600,000. These contracts are renewable annually. The agreements with the Company's key executives contain provisions that apply in case of termination without cause or a change of control. If all executive team members had been dismissed without cause on March 31, 2018, the Company would have had to pay a total amount of \$600,000 as severance. If a change of control had occurred on March 31, 2018, the total amounts payable to the executive team in respect of severance would have totaled \$1,000,000 (assuming they left after a change of control and each named executive opted to receive such compensation). If the assets of the company had been sold to an "arm's length entity" on March 31, 2018, the total amounts payable to the executive team in respect of severance would have totaled \$1,250,000 (assuming they left after a change of control and each named executive opted to receive such compensation)

Subsequent to the nomination of Brian Ostroff as a director of the Company on June 4, 2014, Windermere is considered as a related party because it has significant influence over the Company through its representation on the Board of Directors. All agreements and transactions with Windermere are already disclosed in these financial statements and are therefore not described in this note.

Ocean Partners is also considered as a related party because a director of the Company is one of its managing directors. All agreements and transactions with Ocean Partners are already disclosed in these financial statements and are therefore not described in this note.

14. COMMITMENTS

- a) In August 2012, the Company granted the Lender of the credit line a royalty of \$1 per ton of phosphate concentrate sales from the Lac à Paul project. This royalty may be redeemed at any time through a lump-sum payment of \$6 million. In July 2013, the Company also granted the Lender of the credit line a royalty of \$0.25 per ton of phosphate concentrate sales from the Lac à Paul project. This royalty may be redeemed at any time through a lump-sum payment of \$1.5 million. These royalties will have to be redeemed by the Company for the same amount in the event of a change of control where at least 90% of the issued and outstanding shares of the Company are acquired, purchased or held by a third party, either through a tender offer or other transaction with the same result. The Company also has granted to other parties a 2.25% royalty on the net smelter return. The royalty may be redeemed at any time through a lump-sum payment of \$2.5 million.
- b) The Company granted contracts in relation to the development of the Lac à Paul project for a total of \$242,587. These contracts do not have termination dates and disbursements will be made in accordance with the project's milestones.

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

c) The Company's future minimum operating lease payments for the rent in Chicoutimi office and Lac à Paul camp are as follows:

	Within 1 year	1 to 5 years	After 5 years	Total
March 31, 2018	78,198	-	-	78,198

15. CONTINGENCIES

In the normal course of operations, the Company is exposed to events that could give rise to contingent liabilities. As at the date of issue of the condensed consolidated interim financial statements, the Company was not aware of any significant events that would have a material effect on its condensed consolidated interim financial statements.

16. FINANCIAL INSTRUMENTS AND FINANCIAL RISKS

Classification

The Company's financial instruments as at September 30, 2017 consist of cash and cash equivalents, receivable and other current assets, accounts payable and accrued liabilities, loan and credit lines. The fair value of these financial instruments approximates their carrying value due to their short-term maturity, to current market rates or they bear interest at variable rates.

The classification of financial instruments is summarized as follows:

Classification		Carrying value	Carrying value
		As at March 31, 2018 \$	As at December 31, 2017 \$
Financial assets			
Cash and cash equivalents	Loans and receivables	1,171,609	1,374,881
		<u>1,171,609</u>	<u>1,374,881</u>
Financial liabilities			
Accounts payable and accrued liabilities	Financial liabilities at amortized cost	1,296,624	1,924,840
Loan	Financial liabilities at amortized cost	3,774,786	3,728,306
Credit lines	Financial liabilities at amortized cost	20,494,243	19,642,554
		<u>25,565,653</u>	<u>25,295,700</u>

The Company defines the fair value hierarchy under which its financial instruments are valued as follows: level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities; level 2 includes inputs other than quoted prices in level 1 that are observable for assets or liabilities, either directly or indirectly; and level 3 includes inputs for the asset or liability that are not based on observable market data. Marketable securities were considered a level 1. There was no transfer of hierarchy level as at March 31, 2018 and December 31, 2017.

Financial risks

The Company has exposure to various financial risks, such as credit risk, liquidity risk, interest rate risk, equity risk and currency risk from its use of financial instruments.

Credit risk

The Company's credit risk is primarily attributable to cash and cash equivalents and receivable and other current assets. Cash and cash equivalents are deposited in Canadian chartered bank accounts or invested in a diversified manner in securities having an investment-grade rating (AA-), from which management believes the risk of loss to be minimal. Receivable and other current assets mainly consist of sales taxes receivable and mining tax credits due from the Quebec government. Management believes that the credit risk concentration with respect to financial instruments included in amounts receivable is minimal.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a

ARIANNE PHOSPHATE INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(in Canadian dollars)

downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flows primarily from its financing activities. As at March 31, 2018, the Company had cash and cash equivalents of \$1,171,609 (\$1,374,881 as at December 31, 2017) to settle current liabilities of \$21,790,867 (\$1,924,840 as at December 31, 2017). The Company regularly evaluates its cash position to ensure preservation and security of capital as well as maintenance of liquidity (Refer to note 1 for the use of the going concern assumption).

The following are the contractual maturities of financial liabilities, including interest where applicable as at March 31, 2018:

	Carrying amount	Contractual cash flows	0 to 12 months	12 to 24 months	More than 24 months
	\$	\$	\$	\$	\$
Accounts payable and accrued liabilities	1,296,624	1,296,624	1,296,624	-	-
Loan	3,774,786	3,774,786	328,000	162,356	6,268
Credit line	20,494,243	23,548,402	23,548,402	-	-

Interest rate risk

According to the third non-revolving credit line and amendments made to the first and second credit lines dated October 20, 2015, the interest rate has been modified from a variable to fixed rate and therefore, the Company has no interest rate risk as at December 31, 2017 and March 31, 2018. The Company's policy as it relates to its cash balances is to invest excess cash in financial instruments held with a Canadian chartered bank.

Currency risk

As at March 31, 2018, the Company has a bank account in US dollars for an amount of \$4,014 (\$1,348 as at December 31, 2017). The Company estimates that a variation of $\pm 10\%$ in exchange rates on that date would have resulted in a variation of approximately \$401 in 2017 (\$135 as at December 31, 2017) in net loss.

17. SUBSEQUENT EVENT

On April 3, 2018, Arianne Phosphate announce that it has received a grant of \$ 1.5 million from the Ministry of Energy and Natural Resources of Quebec. This funding has been provided as part of the Government's plan to help advance the Quebec phosphate (apatite) sector. Arianne will be using this funding in support of its previously announced (see Press Release dated November 8, 2017) program to produce additional high-purity phosphate concentrate to fulfil demand from potential customers and, to conduct further pilot-scale tests.